Spots Global Cancer Trial Database for Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Official Title: Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Study ID: NCT04665076
Conditions
Study Description
Brief Summary: This study is a multi-center, non-randomized, single-arm, open clinical trial.
Detailed Description: A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hematology Department, Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China
Contact Details
Name: Baoen Shan, PhD & MD
Affiliation: Hebei Medical University Fourth Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Lihong Liu, PhD & MD
Affiliation: Hebei Medical University Fourth Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
